Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind, Randomised, Parallel-group Trial Investigating Sleep Behaviour and Daytime Performance in Nocturia Patients Treated With Desmopressin Orally Disintegrating Tablets as Compared to Placebo

Trial Profile

A Double-blind, Randomised, Parallel-group Trial Investigating Sleep Behaviour and Daytime Performance in Nocturia Patients Treated With Desmopressin Orally Disintegrating Tablets as Compared to Placebo

Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 Feb 2019

At a glance

  • Drugs Desmopressin (Primary)
  • Indications Nocturia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms DAISS
  • Sponsors Ferring Pharmaceuticals
  • Most Recent Events

    • 08 Feb 2019 This trial has been discontinued in United Kingdom, according to European Clinical Trials Database.
    • 06 Mar 2014 Planned end date changed from 1 Oct 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov.
    • 06 Mar 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top